Soleno Therapeutics – Development and commercialization of novel ...
Soleno is committed to maximizing shareholder value by developing and commercializing innovative therapeutic products with the goal of improving the lives of individuals living with complex, life …
First Developer of Solutions for Mastering Water Sustainably - Soleno
Soleno is your partner for the agriculture of tomorrow. By delivering innovative water management solutions, we can optimize water usage and quality for better biodiversity, soil sustainability and crop …
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
1 day ago · Following its acceptance of the tendered shares, Neurocrine completed its acquisition of Soleno through the merger of a direct wholly owned subsidiary of Neurocrine with and into Soleno, …
Update: Neurocrine Biosciences Completes Acquisition of Soleno ...
2 days ago · Soleno will continue as a wholly owned subsidiary of Neurocrine going forward. In marking the completion of the acquisition, Neurocrine’s CEO Kyle W. Gano, Ph.D., shared, “Today marks an …
Neurocrine pays $2.9B for Soleno, its largest M&A deal ever
Apr 6, 2026 · Neurocine has reached a deal to acquire Soleno Therapeutics for $2.9 billion, bagging recently FDA-approved Vykat XR (diazoxide choline), the first therapy for hyperphagia in patients …
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
1 day ago · Neurocrine completed a $2.9 billion acquisition of Soleno, adding VYKAT XR and reinforcing its rare disease and endocrinology portfolio with a first-in-class Prader-Willi syndrome therapy. …
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus
May 11, 2026 · Soleno Therapeutics (NasdaqCM:SLNO) has entered into a definitive merger agreement with Neurocrine Biosciences, including a cash tender offer. The company also reported its first …
Connecting you to the future of water management - Soleno USA
Subscribe to our newsletter Stay tuned for our latest innovations, technical documents and news. Subscribe case-studies SUSTAINABILITY APPLICATIONS PRODUCTS TECHNOLOGY …
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion ...
Apr 6, 2026 · Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences …
Neurocrine to Acquire Soleno Therapeutics, Expanding Its …
Apr 6, 2026 · Following the successful completion of the tender offer, a wholly owned subsidiary of Neurocrine will merge with Soleno and the outstanding Soleno shares not tendered in the tender …